Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation

Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma

(2015) Mitesh J. Borad et al.   CURRENT OPINION IN GASTROENTEROLOGY

Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study

(2015) Gottfried E Konecny et al.   LANCET ONCOLOGY

Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1

(2015) Y. Nakanishi et al.   MOLECULAR CANCER THERAPEUTICS

Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma

(2015) Daniela Sia et al.   Nature Communications

Identification of Recurrent FGFR3-TACC3 Fusion Oncogenes from Lung Adenocarcinoma

(2014) M. Capelletti et al.   CLINICAL CANCER RESEARCH

Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma

(2014) Rondell P. Graham et al.   HUMAN PATHOLOGY

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

(2014) Robert J Motzer et al.   LANCET ONCOLOGY

Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification

(2014) S. T. Kim et al.   MOLECULAR CANCER THERAPEUTICS

The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor

(2014) Y. Nakanishi et al.   MOLECULAR CANCER THERAPEUTICS

A comprehensive transcriptional portrait of human cancer cell lines

(2014) Christiaan Klijn et al.   NATURE BIOTECHNOLOGY

Anchored multiplex PCR for targeted next-generation sequencing

(2014) Zongli Zheng et al.   NATURE MEDICINE

New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing

(2014) J. S. Ross et al.   ONCOLOGIST

FGFR2 Is Amplified in the NCI-H716 Colorectal Cancer Cell Line and Is Required for Growth and Survival

(2014) Anjili Mathur et al.   PLoS One

Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

(2014) Chaitanya R. Churi et al.   PLoS One

Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities

(2014) Sumera Rizvi et al.   SEMINARS IN LIVER DISEASE

The landscape of kinase fusions in cancer

(2014) Nicolas Stransky et al.   Nature Communications

Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma

(2014) Mitesh J. Borad et al.   PLoS Genetics

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

(2013) R. Dienstmann et al.   ANNALS OF ONCOLOGY

Targeting the Fibroblast Growth Factor Receptors for the Treatment of Cancer

(2013) Steven Lemieux et al.   Anti-Cancer Agents in Medicinal Chemistry

Fibroblast growth factor receptors, developmental corruption and malignant disease

(2013) F. C. Kelleher et al.   CARCINOGENESIS

Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

(2013) T. M. Zaid et al.   CLINICAL CANCER RESEARCH

FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547

(2013) L. Xie et al.   CLINICAL CANCER RESEARCH

Small molecule inhibition of fibroblast growth factor receptors in cancer

(2013) Guang Liang et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

(2013) Yasuhito Arai et al.   HEPATOLOGY

Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours

(2013) Brittany C Parker et al.   JOURNAL OF PATHOLOGY

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

(2013) Yi-Mi Wu et al.   Cancer Discovery

Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatment

(2013) Brittany C. Parker et al.   Chinese Journal of Cancer

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

(2012) P. R. Gavine et al.   CANCER RESEARCH

Fibroblast Growth Factor Receptor Inhibitors

(2012) Suneel Kumar B.V.S et al.   CURRENT PHARMACEUTICAL DESIGN

Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome

(2012) A. Chase et al.   HAEMATOLOGICA

Oncogenic FGFR3 gene fusions in bladder cancer

(2012) Sarah V. Williams et al.   HUMAN MOLECULAR GENETICS

FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

(2012) V. Guagnano et al.   Cancer Discovery

Fibroblast growth factors and their receptors in cancer

(2011) Jørgen Wesche et al.   BIOCHEMICAL JOURNAL

A Novel Mode of Protein Kinase Inhibition Exploiting Hydrophobic Motifs of Autoinhibited Kinases

(2011) Sudharshan Eathiraj et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

(2011) Vito Guagnano et al.   JOURNAL OF MEDICINAL CHEMISTRY

Clinical diagnosis and staging of cholangiocarcinoma

(2011) Boris Blechacz et al.   Nature Reviews Gastroenterology & Hepatology

Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

(2011) Amit Dutt et al.   PLoS One

GP369, an FGFR2-IIIb-Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling

(2010) A. Bai et al.   CANCER RESEARCH

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

(2010) N Turner et al.   ONCOGENE

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

(2010) J. Weiss et al.   Science Translational Medicine

FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review)

(2009) Katoh   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

The FGF family: biology, pathophysiology and therapy

(2009) Andrew Beenken et al.   NATURE REVIEWS DRUG DISCOVERY

Drug-sensitive FGFR2 mutations in endometrial carcinoma

(2008) A. Dutt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA